66 related articles for article (PubMed ID: 3910763)
1. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome.
Siegel JP; Lane HC; Stocks NI; Quinnan GV; Fauci AS
J Biol Response Mod; 1985 Dec; 4(6):596-601. PubMed ID: 3910763
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.
Lotze MT; Frana LW; Sharrow SO; Robb RJ; Rosenberg SA
J Immunol; 1985 Jan; 134(1):157-66. PubMed ID: 3871099
[TBL] [Abstract][Full Text] [Related]
3. Systemic administration of interleukin-2 in humans.
Lotze MT; Robb RJ; Sharrow SO; Frana LW; Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):475-82. PubMed ID: 6334135
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of recombinant interleukin 2 in humans.
Konrad MW; Hemstreet G; Hersh EM; Mansell PW; Mertelsmann R; Kolitz JE; Bradley EC
Cancer Res; 1990 Apr; 50(7):2009-17. PubMed ID: 2317789
[TBL] [Abstract][Full Text] [Related]
5. Treatment of immunodeficiency with interleukin-2: initial exploration.
Mertelsmann R; Welte K; Sternberg C; O'Reilly R; Moore MA; Clarkson BD; Oettgen HF
J Biol Response Mod; 1984 Oct; 3(5):483-90. PubMed ID: 6334136
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic modeling of recombinant interleukin-2 in patients with human immunodeficiency virus infection.
Piscitelli SC; Forrest A; Vogel S; Chaitt D; Metcalf J; Stevens R; Baseler M; Davey RT; Kovacs JA
Clin Pharmacol Ther; 1998 Nov; 64(5):492-8. PubMed ID: 9834041
[TBL] [Abstract][Full Text] [Related]
7. In vivo administration of purified Jurkat-derived interleukin 2 in mice.
Donohue JH; Lotze MT; Robb RJ; Rosenstein M; Braziel RM; Jaffe ES; Rosenberg SA
Cancer Res; 1984 Apr; 44(4):1380-6. PubMed ID: 6608405
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients.
Piscitelli SC; Wells MJ; Metcalf JA; Baseler M; Stevens R; Davey RT
Pharmacotherapy; 1996; 16(5):754-9. PubMed ID: 8888071
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 2 enhances the natural killer cell activity of acquired immunodeficiency syndrome patients through a gamma-interferon-independent mechanism.
Rook AH; Hooks JJ; Quinnan GV; Lane HC; Manischewitz JF; Macher AM; Masur H; Fauci AS; Djeu JY
J Immunol; 1985 Mar; 134(3):1503-7. PubMed ID: 3918102
[TBL] [Abstract][Full Text] [Related]
10. The fate of interleukin-2 after in vivo administration.
Donohue JH; Rosenberg SA
J Immunol; 1983 May; 130(5):2203-8. PubMed ID: 6601147
[TBL] [Abstract][Full Text] [Related]
11. Use of interleukin-2 in patients with acquired immunodeficiency syndrome.
Lane HC; Siegel JP; Rook AH; Masur H; Gelmann EP; Quinnan GV; Fauci AS
J Biol Response Mod; 1984 Oct; 3(5):512-6. PubMed ID: 6334138
[TBL] [Abstract][Full Text] [Related]
12. [In vitro synergic lymphocyte stimulation in HIV-1 infected patients using inosine derivatives and radio-detoxified endotoxin].
Ongrádi J; Hadden JW; Bertók L; Specter S; Nelson R; Friedman H
Orv Hetil; 1995 Mar; 136(12):653-9. PubMed ID: 7708388
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics after discontinuous intravenous administration of azlocillin].
Naber K; Adam D
Arzneimittelforschung; 1983; 33(3):429-32. PubMed ID: 6683518
[TBL] [Abstract][Full Text] [Related]
15. Alteration in indinavir clearance during interleukin-2 infusions in patients infected with the human immunodeficiency virus.
Piscitelli SC; Vogel S; Figg WD; Raje S; Forrest A; Metcalf JA; Baseler M; Falloon J
Pharmacotherapy; 1998; 18(6):1212-6. PubMed ID: 9855318
[TBL] [Abstract][Full Text] [Related]
16. [Biological properties and therapeutic use of interleukin 2 (IL-2)].
Robak T
Postepy Hig Med Dosw; 1995; 49(3):367-93. PubMed ID: 8657637
[TBL] [Abstract][Full Text] [Related]
17. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
Levine AM; Tulpule A; Espina B; Boswell W; Buckley J; Rasheed S; Stain S; Parker J; Nathwani B; Gill PS
Cancer; 1996 Aug; 78(3):517-26. PubMed ID: 8697399
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunological effects of treatment with murine anti-CD3 monoclonal antibody along with interleukin 2 in patients with cancer.
Hank JA; Albertini M; Wesly OH; Schiller JH; Borchert A; Moore K; Bechhofer R; Storer B; Gan J; Gambacorti C
Clin Cancer Res; 1995 May; 1(5):481-91. PubMed ID: 9816007
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of interleukin-2 following intravenous injection in hemodialysis patients with renal cell carcinoma.
Kamikawa S; Sugimoto T; Asai T; Ishii K; Kim T
Ther Apher Dial; 2008 Feb; 12(1):67-71. PubMed ID: 18257815
[TBL] [Abstract][Full Text] [Related]
20. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
Eppler SM; Combs DL; Henry TD; Lopez JJ; Ellis SG; Yi JH; Annex BH; McCluskey ER; Zioncheck TF
Clin Pharmacol Ther; 2002 Jul; 72(1):20-32. PubMed ID: 12152001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
